Top Story

Molecular subtypes of stage III colon cancer linked to different patient outcomes

January 30, 2015

Researchers have identified subtypes of stage III colon cancer based on molecular markers associated with differences in clinical and pathological features as well as disease-free survival.

Investigators prospectively collected 2,720 stage III colon cancer samples from participants in an adjuvant chemotherapy trial. They used a polymerase chain reaction-based assay to identify mutations in BRAF (V600E) and KRAS oncogenes, and identified tumors deficient or proficient in DNA mismatch repair (MMR) based on detection of MLH1, MSH2 and MSH6 proteins and MLH1 methylation. Then they characterized tumor subtypes into five groups with respect to clinicopathologic features and rates of disease-free survival (DFS), and validated the findings using separate tumor samples from 783 other patients with stage III cancer.

Lecia V. Sequist, MD, MPH In the Journals

First-line afatinib extended OS in exon 19 deletion-positive lung adenocarcinoma

January 30, 2015
Patients with lung adenocarcinoma who harbored exon 19 deletion EGFR mutations experienced significantly longer OS when treated with first-line afatinib instead of…
In the Journals

Additional CT scans increased risk for second primary malignancy in patients with non-Hodgkin's lymphoma

January 30, 2015
Patients with non-Hodgkin’s lymphoma who underwent more frequent surveillance CT scans demonstrated an increased risk for a secondary primary malignancy, according…
In the JournalsPerspective

GTX effective neoadjuvant treatment in locally advanced pancreatic cancer

January 29, 2015
Patients with locally advanced, unresectable pancreatic adenocarcinoma experienced favorable survival when they received neoadjuvant gemcitabine, docetaxel and…
FDA NewsDrug Pipeline

Tarextumab granted orphan drug designation for pancreatic, small cell lung cancers

January 29, 2015
The FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and small cell lung cancer, the drug’s manufacturer announced…
More News Headlines »
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »